Eledon Pharmaceuticals Inc
ELDN
Market Cap$161.08M
Close$
$0.04
98.5% downside
Current Fair Value
98.5% downsideOvervalued by 98.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $161.08 Million |
|---|---|
| Enterprise Value | $156.37 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.73 |
| Beta | -0.13 |
| Outstanding Shares | 77,126,763 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -10.89 |
|---|---|
| PEG | 29.51 |
| Price to Sales | - |
| Price to Book Ratio | 2.69 |
| Enterprise Value to Revenue | 814.41 |
| Enterprise Value to EBIT | -2.01 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Eledon Pharmaceuticals Inc
10 employees
CEO: Gregory Flesher Novus Therapeutics, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-bas...